• Assessment of tumor suppressor promoter methylation in healthy individuals 

      Poduval, Deepak; Berge, Elisabet Ognedal; Sichmanovà, Zuzana; Valen, Eivind; Iversen, Gjertrud Titlestad; Minsaas, Laura; Lønning, Per Eystein; Knappskog, Stian (Journal article; Peer reviewed, 2020-08)
      Background The number of tumor suppressor genes for which germline mutations have been linked to cancer risk is steadily increasing. However, while recent reports have linked constitutional normal tissue promoter methylation ...
    • Filamin A binds to CCR2B and regulates its internalization 

      Minsaas, Laura; Planagumà, Jesús; Madziva, Michael; Krakstad, Beate F.; Masià-Balagué, Míriam; Katz, Arieh A.; Aragay, Anna M. (Peer reviewed; Journal article, 2010-08-17)
      The chemokine (C-C motif) receptor 2B (CCR2B) is one of the two isoforms of the receptor for monocyte chemoattractant protein-1 (CCL2), the major chemoattractant for monocytes, involved in an array of chronic inflammatory ...
    • Filamin A-Hinge Region 1-EGFP: A Novel Tool for Tracking the Cellular Functions of Filamin A in Real-Time 

      Planagumà, Jesús; Minsaas, Laura; Pons, Mónica; Myhren, Lene Elisabeth; Garrido, Georgina; Aragay, Anna M. (Peer reviewed; Journal article, 2012-08-01)
      Background: Filamin A (FLNa) is an actin-crosslinking protein necessary for stabilizing the cell surface, organizing protrusive activity and for promoting efficient cellular translocation. Recently, our group demonstrated ...
    • Olaparib monotherapy as primary treatment in unselected triple negative breast cancer 

      Eikesdal, Hans Petter; Yndestad, Synnøve; Elzawahry, Asmaa; Llop-Guevara, Alba; Gilje, Bjørnar; Blix, Egil Støre; Espelid, Helge; Lundgren, Steinar; Geisler, Jürgen; Vagstad, Geirfinn; Venizelos, Andreas; Minsaas, Laura; Leirvaag, Beryl; Gudlaugsson, Einar; Vintermyr, Olav Karsten; Aase, Hildegunn Siv; Aas, Turid; Balmaña, Judith; Serra, Violeta; Janssen, Emiel; Knappskog, Stian; Lønning, Per Eystein (Journal article; Peer reviewed, 2020)
      Background The antitumor efficacy of PARP inhibitors (PARPi) for breast cancer patients harboring germline BRCA1/2 (gBRCA1/2) mutations is well established. While PARPi monotherapy was ineffective in patients with metastatic ...